BRUS
-345
5
Блог им. Alex_Hurko:

Аналитика на 16 мая

/uploads/images/ Alex_Hurko
Alex_Hurko 16 мая 2013, 16:56
Спайдер незначительно изменяется открытием торгов на NYSE.
 Европейские индексы на положительной территориии.
SPY (внутридневной график) боковое двиежние премаркете. Сопротивление: 166.25 Поддержка: 165.50

Премаркет NYSE/NASDAQ:
Gapping up:
In reaction to strong earnings/guidance: EGLE +12.4%, CSCO +10.5%, KSS +6.8%, DANG +4.3%, DDS +3.8%, AV +2.8%, (ticking higher), NTES +2.6%.

M&A related: ACT +1.0% (ongoing M&A realted speculation, initially traded higher following WSJ story that Novartis is considering if it should enter the takeover battle for ACT; hearing NVS denied rumors).

A few financial related names showing strength: NBG +6.5%, RBS +2.1%, LYG +1.1%, BCS +1%.

Select solar stocks seeing continued strength: SPWR +5.6% (upgraded to Outperform at Cowen), TSL +3.4%, CSIQ +3.2%.

Select CSCO peers/tech names showing strength: JNPR +3.1%, BRCD +2.1% (Soros Fund Mgmt discloses notable new Q1 position), FNSR +1.6%, AMAT +1.4%, CIEN +1.3%, VMW +1.3% (Soros Fund Mgmt discloses notable new Q1 position), EMC +1.2%.

Other news: RGDX +29.6% (thinly traded, Response Genetics, Inc. Announces Contract With Blue Shield of California), TSLA +11.1% (filed for a mixed securities shelf offering consisting of common stock and debt securities, announces offerings of common stock and convertible senior notes, CEO Musk indicates interest in buying up to 1.2 mln shares through shelf offering/private placement), SPPI +7.9% (seeing notable premarket strength, checking around for catalyst (may be ASCO presentation slides out), YRCW +6.1% (continued strength), HALO +4.4% (to present new data on PEGPH20 in pancreatic cancer at American Society of Clinical Oncology Annual Meeting ), LMCA +4% (Berkshire Hathaway discloses 5.03% passive stake in 13G filing), ROSG +4% (continued strength following late surge higher), ONTY +3.4% (announces results from randomized Phase III START trial of the investigational MUC1 antigen-specific cancer immunotherapy L-BLP25 in patients with unresectable, locally advanced Stage III non-small cell lung cancer; primary endpoint of improving overall survival was not met), CBI +3% (Berkshire reports new Q1 stake in CBI), JCP +2.3% (strength ahead of earnings and following KSS results), SCTY +2.3% (following filing indicating Elon Musk buying TSLA shares), NAVB +2.1% (Nordion signs contract manufacturing agreement with Navidea Biopharmaceutical), MU +1.7% (Micron announces issuance by Tokyo High Court of Order dismissing creditor appeals), INVN +1.4% (provides legal matters update: co brought a legal suit against ST Microelectronic), ZTS +1.3% (FDA approves APOQUEL to Control Itch and Inflammation in Allergic Dogs), IACI +0.7% (Greenlight discloses new position), FANG +0.7% (prices 4.5 mln shares of common stock at a price of $29.25 per share), POT +0.5% ( increases quarterly dividend).

Analyst comments: PANW +0.5% ( upgraded to Overweight from Equal-Weight at Morgan Stanley), AMZN +0.3% (initiated with a Buy at Lazard)
Gapping down:
In reaction to disappointing earnings/guidance: VRML -5.3% (light volume), NQ -5.5%, ACXM -3.9%, (light volume), YOKU -2.7%, WMT -2%, JACK -0.9%.

Metals/mining stocks trading lower: AU -3.4%, IAG -2.8%, EGO -2.8%, RIO -2.2%, AUY -1.7%, SLW -1.7%, RIO -1.6%, NEM -1.5%, GLD -1.4%, MT
Отчеты компаний:
Сегодня перед открытием:
BRC CTCH DANG DSCI EDAP FLO IMOS KSS PBH SOL WMT
Вчера после закрытия:
ACXM ADAT AGRO ANW BAGR BLIN BSPM CEP CSCO DDS DSS EFOI EGLE JACK KGJI LWAY MBND NQ NTES ONP ONSM OVRL RLGT SAPE SB SBSA SKX TRIT VRML WYY YOKU Торговые идеи NYSE и NASDAQ:
JNPR – шорт ниже 17.50
CBI – шорт ниже 60.00
NQ – шорт ниже 9.00 с потенциалом до 50 центов, выше 9.00 возможен лонг.
DDR – лонг выше максимума премаркета.
KSS – лонг выше уровней премаркета.
NTES – лонг выше 62.00

Оригинал статьи: shark-traders.com/blog/analitika-na-16-maya/
Оценка: 0

Вставка изображения

Вставить в блог
нет комментариев RSS

Только зарегистрированные и авторизованные пользователи могут оставлять комментарии.


Главную ленту сайта можно читать в популярных социальных сетях. Добавьте Блогберг в друзья: